MaxCyte (MXCT) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
MaxCyte, Inc. has appointed Cynthia Collins to its Board of Directors, enhancing its leadership with her extensive experience in cell therapy and genetic medicine. Collins, who has a notable background as CEO of several biotech companies, will serve on the board’s compensation committee. This appointment aligns with MaxCyte’s strategy to advance its cell engineering platform and support the development of next-generation cell-based therapies.
For further insights into MXCT stock, check out TipRanks’ Stock Analysis page.
